Ignite Creation Date:
2025-12-25 @ 4:12 AM
Ignite Modification Date:
2026-01-26 @ 1:54 PM
Study NCT ID:
NCT02718820
Status:
COMPLETED
Last Update Posted:
2024-01-09
First Post:
2016-03-15
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck Cancer
Sponsor:
Medical University of Vienna
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-03
Start Date Type:
None
Primary Completion Date:
2021-12
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-12
Completion Date Type:
ACTUAL
First Submit Date:
2016-03-15
First Submit QC Date:
None
Study First Post Date:
2016-03-24
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2022-05-22
Results First Submit QC Date:
None
Results First Post Date:
2023-12-04
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-12-17
Last Update Post Date:
2024-01-09
Last Update Post Date Type:
ACTUAL